Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $500K | — | — | — | — | — | — | — |
| Operating income | -$4.52M | -$6.76M | -$11.6M | -$12.7M | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M |
| Operating margin | — | -1352.2% | — | — | — | — | — | — | — |
| Net income | -$4.26M | -$5.73M | -$10.6M | -$12.3M | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M |
| Net margin | — | -1146.8% | — | — | — | — | — | — | — |
| EPS (diluted) | -$0.72 | -$0.74 | -$0.89 | -$0.78 | -$0.65 | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.90M | -$5.70M | -$9.10M | -$9.19M | -$12.3M | -$11.5M | -$18.7M | -$22.1M | -$29.1M |
| Capital expenditures | $22.0K | $50.0K | $2.00K | $47.0K | $22.0K | $81.0K | $24.0K | $25.0K | $40.0K |
| Free cash flow | -$3.92M | -$5.75M | -$9.10M | -$9.23M | -$12.3M | -$11.6M | -$18.8M | -$22.1M | -$29.1M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.35M | $16.8M | $3.88M | $7.41M | $4.71M | $4.73M | $4.54M | $3.02M | $15.6M |
| Total assets | $1.80M | $18.3M | $9.05M | $28.1M | $45.6M | $34.4M | $54.2M | $46.3M | $61.4M |
| Shareholders' equity | $799K | $17.0M | $7.62M | $26.0M | $44.0M | $31.8M | $51.1M | $40.7M | $56.1M |
| Retained earnings | -$40.2M | -$46.0M | -$56.6M | -$68.9M | -$82.5M | -$96.2M | -$116M | -$140M | -$173M |
| Shares (wtd avg diluted) | 6.37M | 12.0M | 12.0M | 18.7M | 20.8M | 26.4M | 32.6M | 40.4M | 47.0M |
Every figure is extracted from DiaMedica Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.